ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the synergistic protective effect of linezolid (LZD) combined with
methodsFifty C57BL/6J mice with pneumonia induced by tracheal instillation of MRSA were randomized equally into model group, low- and high-dose XBJ treatment groups (13 and 80 mg·kg
resultsThe combined treatment with LZD and XBJ significantly improved survival rates of the mouse models, reduced inflammatory cell infiltration and lung injury scores, decreased the levels of IL-6, TNF-α, IL-1β, and IL-18, and downregulated mRNA and protein expressions of Hla, NLRP3, caspase-1, and ASC. XBJ alone showed no antibacterial activity against MRSA but inhibited α-hemolysin (Hla) secretion both
conclusionsLZD combined with XBJ produces enhanced efficacy for improving MRSA pneumonia possibly due to XBJ-induced inhibition of NLRP3-mediated inflammatory response via inhibiting α-hemolysin secretion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.